In a Q&A, Recursion’s incoming CEO acknowledges hype around the idea of using AI to expedite drug development, and says it's ...

Few would place Recursion Pharmaceuticals (NASDAQ: RXRX), a little-known biotech company, in the same league as these tech ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

Is that the case? Let's look into it and decide whether the company is worth investing in.